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Accepted 30 June 2014; Published online 30 August 2014AbstractObjectives: It is widely acknowledged that the performance of diagnostic and prognostic prediction models should be assessed in
external validation studies with independent data from ‘‘different but related’’ samples as compared with that of the development sample.
We developed a framework of methodological steps and statistical methods for analyzing and enhancing the interpretation of results from
external validation studies of prediction models.
Study Design and Setting: We propose to quantify the degree of relatedness between development and validation samples on a scale
ranging from reproducibility to transportability by evaluating their corresponding case-mix differences. We subsequently assess the models’
performance in the validation sample and interpret the performance in view of the case-mix differences. Finally, we may adjust the model to
the validation setting.
Results: We illustrate this three-step framework with a prediction model for diagnosing deep venous thrombosis using three validation
samples with varying case mix. While one external validation sample merely assessed the model’s reproducibility, two other samples rather
assessed model transportability. The performance in all validation samples was adequate, and the model did not require extensive updating
to correct for miscalibration or poor fit to the validation settings.
Conclusion: The proposed framework enhances the interpretation of findings at external validation of prediction models.  2015 The
Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://creativecommons.org/licenses/
by-nc-sa/3.0/).
Keywords: Case mix; Reproducibility; Transportability; Generalizability; Prediction model; Validation1. Introduction
Clinical prediction models are commonly developed to
facilitate diagnostic or prognostic probability estimations
in daily medical practice. Such models are typically
developed by (statistically) associating multiple predic-
tors with outcome data from a so-called derivation or
development sample. Well-known examples are the Wells
models for diagnosing deep venous thrombosis, the Gail
model for prediction of breast cancer incidence [1],Funding: This work was supported by the Netherlands Organiza-
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0895-4356/ 2015 The Authors. Published by Elsevier Inc. This is an open acce
censes/by-nc-sa/3.0/).and the Framingham risk scores for cardiovascular risk
assessment [2].
As prediction models are developed to be applied in new
individuals, their value depends on their performance
outside the development sample [3e7]. It is therefore rec-
ommended to quantify the predictive accuracy of novel pre-
diction models in different samples (as compared with the
development sample) from the same or similar target pop-
ulations or domains [3,4,6e12]. These so-called (external)
validation studies may range from temporal (eg, sample
from the same hospital or primary care practice only later
in time), to geographical (eg, sample from different hospi-
tal, region, or even country), to validations across different
medical settings (eg, from secondary to primary care
setting or vice versa) or different target populations or do-
mains (eg, from adults to children) with increasingly
different study samples or case mix between development
and validation samples [3,4,6,13].ss article under the CC BY-NC-SA license (http://creativecommons.org/li-
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Key findings
 The proposed methodological framework for pre-
diction model validation studies may enhance the
interpretation of results from validation studies.
Important issues are judging to what extent the
subjects in the validation sample are truly different
from the development sample, how the case mix of
the validation sample at hand can be placed in view
of other validation studies of the same model, and
to what extent the (clinical) transportability or
rather (statistical) reproducibility of the model is
studied.
What this adds to what was known?
 The value of any developed (diagnostic or prog-
nostic) prediction model depends on its perfor-
mance outside the development sample, and
therefore it is widely recommended to externally
validate its predictive accuracy in samples from
plausibly related source populations (as compared
with the development sample). It is often unclear
how results from validation studies relate to the
actual generalizability of the prediction model
and how researchers should interpret good or poor
model performance in the validation sample. By
quantifying the relatedness between the develop-
ment and validation samples, it becomes possible
to interpret estimated model performance in
terms of (clinical) transportability or (statistical)
reproducibility.
 Internal validation studies assess model repro-
ducibility.
 External validation studies do not necessarily
assess model transportability (to a large extent).
What is the implication and what should change
now?
 When externally validating a prediction model,
researchers should evaluate and quantify the relat-
edness between the population of the development
and validation samples; otherwise, inferences on
the actual clinical value or transportability of a
prediction model may be misleading and cause
prediction models to be implemented in incompat-
ible populations.
Unfortunately, the concept of external validation re-
mains rather abstract and loosely defined. It is often unclear
to which extent individuals from the validation sample
(meaningfully) differ or may differ from the developmentsample. One often still has to speculate how an estimated
model performance (eg, discrimination or calibration) in
an external validation study should be interpreted, that is,
under which conditions the model can successfully be im-
plemented across other plausibly related populations.
Justice et al. and others [6,7,14,15] attempted to refine
the interpretation of validation study results by distinguish-
ing between model reproducibility and model transport-
ability. Model reproducibility refers that a model
performs sufficiently accurate across new samples from
the same target population. This can also be approximated
with resampling techniques using the development data set
only, such as bootstrapping or cross-validation techniques,
commonly referred to as internal validation of a prediction
model [11,12]. Transportability refers that a model
performs well across samples from different but related
source populations and can only be assessed in external
validation studies. The degree of relatedness between the
development and (external) validation samples is often un-
clear and, thereby, obfuscates the extent of transportability
that is actually being tested. It may, for instance, be
possible that some external validation studies rather reflect
a model’s reproducibility, for example, when the
development and validation samples have a very similar
case mix.
We anticipate that a framework for quantifying differ-
ences in case mix between the development and validation
sample(s) would help to interpret the results of external
validation studies of prediction models. In particular, these
differences could indicate the extent to which an external
validation study assesses the model’s reproducibility or its
transportability. We hereto propose a framework of meth-
odological steps and address statistical methods for
analyzing and interpreting the results of external validation
studies. We illustrate the use of our framework in an empir-
ical example on validation of a developed prediction model
for the presence of deep vein thrombosis (DVT) using a
large individual participant data set with different valida-
tion samples, with varying case mix. We aim to improve
the inference making of studies aimed at testing of predic-
tion models in new participant samples to better determine
whether a prediction model is clinically valuable or merely
statistically reproducible [6]. The framework thus facili-
tates faster and wider implementation of genuinely useful
models and allows a speedier identification of models that
are of limited value [16].2. Empirical example data
DVT is a blood clot that forms in a leg vein and may
migrate to the lungs leading to blockage of arterial flow,
preventing oxygenation of the blood and potentially
causing death. Multivariable diagnostic prediction models
have been proposed during the past decades to safely
exclude DVT without having to refer for further burdening
(reference standard) testing. Physicians may, however,
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tient(s) represent a specific subgroup, such as elderly co-
morbid patients [17], that was not well represented in the
development sample. For this article, we hypothesize that
it is yet unclear to what extent the developed DVT diag-
nostic prediction models are valid across samples of the
same or of different (but related) target populations because
the performance of a prediction model may change accord-
ing to the characteristics of the patients or clinical setting
(eg, primary or secondary care).
To illustrate our framework, we used individual partici-
pant data (IPD) from four different data sets with varying
case mix (Table 1) to develop and test a multivariable diag-
nostic model for predicting the presence or absence of
DVT. Specifically, we used one data set (n 5 1,295) to
develop a logistic regression model with seven predefined
(based on previous developed prediction models) patient
characteristics and the D-dimer test result (Table 2). Next,
we assessed the model performance in the three remaining
validation data sets (n1 5 791, n2 5 1,028, and n3 5
1,756), each with different case mix. We note that data
are used for illustration purposes of our framework only
and not to present the optimal diagnostic strategy in the
validated settings. For further details on these studies, we
refer to the literature [18].3. Methods
Fig. 1 describes the steps of our proposed methods and
steps for analysis and enhanced interpretation of the results
of external validation studies. In the first step, we quantify
to what extent the (case mix of the) development and vali-
dation samples are related. In the second step, we assess the
model’s predictive accuracy in the development and valida-
tion samples to identify the extent to which its predictive
mechanisms differ or remain accurate in the validation sam-
ple as compared with the development sample. In the third
step, we combine the results from the preceding steps to
judge whether the model’s performance in the validation
sample rather reflects a degree of reproducibility or trans-
portability. In this step, we also indicate what type of revi-
sions to the model, based on the validation sample at hand,Table 1. Baseline table for four deep vein thrombosis (DVT) data sets
Study-level characteristics Development
Line of care Primary
N 1,295
Incidence DVT (%) 22
Male gender (%) 36
Oral contraceptive use (%) 10
Presence of malignancy (%) 6
Recent surgery (%) 14
Absence of leg trauma (%) 85
Vein distension (%) 20
Calf difference  3 cm (%) 43
D-dimer abnormal (%) 69may be necessary in case of (too) poor predictive accuracy.
We describe a straightforward analytic and judgmental im-
plementation for each step and illustrate the approach using
the empirical example data.
3.1. Step 1: Investigate relatedness of development and
validation sample
This first step aims to quantify to what extent the develop-
ment and validation samples are related. Two samples can
have any degree of relatedness ranging from ‘‘identical’’ to
‘‘not related at all’’ [4,6,7]. Different but related samples are
located between these extremes, and determination of their
(relative) position is essential for interpreting the results of a
validation study and make inferences on the transportability
of a model. Typically, two (or more) samples differ when the
distribution of their subject characteristics including outcome
occurrence (case mix) or the predictor effects (regression co-
efficients) differ [6,13,19e21]. Consequently, it seems useful
to evaluate the extent towhich the development and validation
samples have (1) a similar case mix (ie, including outcome
occurrence) and (2) share common predictor effects.
The most common approach for evaluating relatedness
of case mix between the development and validation sam-
ples is to compare the distribution of each context-
important subject characteristic separately, including the
predictors in the validated model and outcome, using sum-
mary measures such as percentage, mean, standard devia-
tion (SD), and range [4e6,22]. This approach is useful
for comparing specific characteristics across study samples;
an overall judgment of the relatedness between samples re-
mains hard. For instance, Table 1 reveals that the develop-
ment sample and the validation study 1 have a very similar
case mix of predictor variables but a different outcome
occurrence (22% vs. 16%). In validation study 3, however,
the outcome occurrences are similar, but the case mix
considerably differs. It is not directly clear, however, which
of the validation samples is now more similar to the devel-
opment sample and would lead to smaller or larger change
in the predictive performance of the model as compared
with the performance found in the development set.
Next to the specific characteristic distribution compari-
sons, the heterogeneity in predictoreoutcome associationsValidation 1 Validation 2 Validation 3
Primary Primary Secondary
791 1,028 1,756
16 13 23
38 37 37
10 0 5
5 5 13
13 8 11
82 72 85
20 15 16
41 30 24
72 46 52
Table 2. Estimated regression coefficients and corresponding standard errors (SE) for four primary care deep vein thrombosis (DVT) data sets
Development Validation 1 Validation 2 Validation 3
N 1,295 791 1,028 1,756
Constant (model intercept) 5.02 (0.38) 6.71 (1.06) 4.67 (0.37) 4.46 (0.29)
Male gender 0.71 (0.16) 0.40 (0.22) 0.60 (0.21) 0.49 (0.14)
Oral contraceptive use 0.76 (0.27) 0.47 (0.35) 7.02 (58.62) 0.49 (0.32)
Presence of malignancy 0.50 (0.26) 0.07 (0.43) 0.68 (0.36) 0.30 (0.18)
Recent surgery 0.42 (0.20) 0.55 (0.28) 0.04 (0.38) 0.49 (0.19)
Absence of leg trauma 0.67 (0.22) 0.81 (0.31) 0.55 (0.25) 0.25 (0.21)
Vein distension 0.53 (0.17) 0.23 (0.25) 0.22 (0.26) 0.58 (0.18)
Calf difference  3 cm 1.15 (0.15) 0.87 (0.21) 0.87 (0.21) 1.42 (0.14)
D-dimer abnormal 2.43 (0.30) 3.95 (1.01) 2.40 (0.30) 2.96 (0.22)
The linear predictor for a subject (given by the model from the development sample) is as follows: 5.02 þ (0.71 male gender)þ (0.76  OC
use) þ (0.50  presence of malignancy) þ (0.42  recent surgery) þ (0.67  absence of leg trauma) þ (0.53  vein distension) þ (1.15  calf
difference  3 cm) þ (2.43  abnormal D-dimer). The probability (or risk) of DVT for the same subject is given by 1/[1 þ exp(linear predictor)].
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be evaluated by, for example, refitting the original model
in the validation sample (Table 2). Unfortunately, also for
this approach, it is not directly clear how to summarize dif-
ferences in estimated regression coefficients (or corre-
sponding adjusted odds ratios) as heterogeneity between
the underlying target populations and how to judge to what
extent a model’s performance in other validation studies is
affected.
We here propose two statistical approaches that use IPD
from the development and validation samples to calculate
an overall measure of their (dis)similarity. The first
approach calculates a summary measure of relatedness
based on how well the study individuals from both samples
can be distinguished. The second approach assesses to
which extent the predicted risk distributions of the develop-
ment and validation samples diverge.
3.1.1. Approach 1: Distinguishing between individuals
of validation and development sets
The relatedness between two samples is typically tested
by assuming an underlying (eg, multivariate normal)Fig. 1. Proposed approach to external validation studies. Typical validatdistribution of subject characteristics. This strategy is, how-
ever, often undesirable because it cannot adequately ac-
count for dichotomous or nonlinear variables. We
therefore relate to the principles of discriminant analysis
and the Mahalanobis distance metric by considering a
generalization of Hotelling T2 [23]. In particular, we pro-
pose to quantify to which extent individuals from the devel-
opment and validation samples can be distinguished and
use this as a measure of nonrelatedness. We hereto estimate
a binary logistic regression model, further referred to as
membership model, to predict the probability that an indi-
vidual belongs to (is a member of) the development sample
as compared with the validation sample. Hence, the depen-
dent variable of this model is ‘‘1’’ for participants of the
development set and ‘‘0’’ for those of the validation set.
This model should at least include as independent variables
the predictors and outcome from the original prediction
model to ensure that model performance can (at least
partially) be interpreted in terms of its considered predic-
tors and outcome. It may be clear that if the membership
model discriminates poorly (or well), both samples are
strongly (or not much) related in terms of the consideredion studies are restricted to step 2: ‘‘Assess model performance’’.
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ability can be quantified using measures such as the concor-
dance (c) statistic.
3.1.2. Approach 2: Comparing the predicted risks be-
tween development and validation samples
It is also possible to use the IPD of both samples to
directly compare the distribution of the model’s predicted
risks in the development and validation samples [11,20].
This can be achieved by calculating the spread, here
defined as the SD, and the mean of the linear predictor
(LP) of the original model in the development and valida-
tion samples. Because the LP is the logit transformation of
the predicted risks in logistic regression, its interpretation
is fairly straightforward. An increased (or decreased)
variability of the LP indicates more (or less) heterogeneity
of case mix between the development and validation sam-
ples and thus of their overarching target populations. As
the case-mix heterogeneity increases, individuals have a
larger variety of patient characteristics, and the model
tends to discriminate better [20,24]. Specifically, the
discriminative ability may improve (or deteriorate) when
the SD of the LP increases (or decreases) because individ-
ual risk estimates become more (or less) separable between
both samples. Conversely, differences in mean of the LP
between the development and validation samples reflect
the difference in overall (predicted) outcome frequencyd
that is, in fact a reflection of case mix severitydand
may therefore reveal the model’s calibration-in-the-large
in the validation sample [25].
3.1.3. Empirical example
Results from the empirical example (Fig. 2) demonstrate
that approach 1 and the distribution of the LP (approach 2)Fig. 2. Results from step 1 in the empirical example. Results of analyzing the
model. The y-axis reflects the extent to which the validation sample is differ
tistic of the membership model). In the left graph, the x-axis reflects the p
standard deviation (SD) of the linear predictor. In the right graph, the x-ax
Circle, validation study 1; square, validation study 2; triangle, validation stgenerally lead to similar conclusions. Specifically, we
found that it was difficult to distinguish between individ-
uals from the development sample and validation study 1.
The concordance statistic of the membership model, cm,
was 0.56 with 95% confidence interval of 0.54, 0.59 indi-
cating that both samples are largely the same. Approach
2 reveals that both samples also had a similar SD of the
LP (1.45 vs. 1.47) and similar mean of the LP (1.72 vs.
1.75). Hence, both approaches show that the development
sample and validation study 1 had a similar distribution of
case mix, and we can expect similar model performance in
both samples.
For validation studies 2 and 3, we found an increased
spread of the LP and a decreased average of the LP. The
membership models indicated that individuals from the
development and validation samples could be distinguished
more easily and that their case mix was indeed much less
related to the case mix of the development sample (cm 5
0.71 and cm 5 0.68 respectively).3.2. Step 2: Assessment of the model’s performance in
the validation study
In this second step, we evaluate the originally developed
model’s performance in the validation sample. This is typi-
cally quantified in terms of calibration and discrimination
[11,12,26]. Calibration reflects the extent to which the pre-
dicted probabilities and actual probabilities agree, whereas
discrimination is the ability to distinguish high-risk from
low-risk individuals. Here, we focus on the calibration-
in-the-large plus calibration slope and the c-statistic as
summary measures of calibration and discrimination,
respectively [11,27e30]. The calibration slope can be used
as a statistic for evaluating to which extent the model’svalidation sample (median with 95% CI) and validating the prediction
ent but related to the development sample (as indicated by the c-sta-
otential for good performance indicated by the relative difference in
is reflects the difference between the means of the linear predictors.
udy 3.
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ple. Finally, we recommend visual inspection of the calibra-
tion plot, in which groups of predicted probabilities are
plotted against actually observed outcomes and perfect pre-
dictions should be on the 45 line [27].
3.2.1. Calibration-in-the-large
This statistic is given as the intercept term a from the
recalibration model logitðyÞ5aþ logitðbyÞ [11]. It quan-
tifies whether the average of predictions corresponds with
the average outcome frequency and ideally equals 0.
Values below (or above) this value indicate that the model
overestimates (or respectively underestimates) the
outcome. By definition, the calibration-in-the-large is al-
ways optimal (0) in the development sample of the predic-
tion model [11,31]. Consequently, it is a useful statistic for
identifying whether unexplained differences exist in the
outcome frequency of the validation sample, for example,
because of mechanisms not captured by the included pre-
dictors [4,25,32].
3.2.2. Calibration slope
The calibration slope, denoted as boverall, can be estimated
from the recalibration model logitðyÞ5aþ boverall logitðbyÞ. It
reflects whether predicted risks are appropriately scaled with
respect to each other over the entire range of predicted prob-
abilities (boverall 5 1) [29,33]. Typically, boverall O 1 occurs
when predicted probabilities do not vary enough (eg, pre-
dicted risks are systematically too low) and 0 ! boverall !
1 occurs when they vary too much (eg, predicted risks are
too low for low outcome risks and too high for high outcome
risks). A poor calibration slope (0! boverall! 1) usually re-
flects overfitting of the model in the development sample but
may also indicate inconsistency of predictor effects between
the development and validation samples [11,21,27,34e36].
3.2.3. Concordance statistic
The c-statistic represents the probability that individ-
uals with the outcome receive a higher predicted probabil-
ity than those without. It corresponds to the area under the
receiver operating characteristic curve for binary out-
comes and can range from 0.5 (no discrimination) to 1.0
(perfect discrimination). Because the c-statistic reveals
to what extent the prediction model can rank order the in-
dividuals according to the outcome in the validation sam-
ple, it is a useful tool for evaluating its discriminative
value.
3.2.4. Empirical example
In validation study 1, we found that the discriminative
ability of the developed model slightly decreased
(Fig. 3). Predicted risks were systematically too high (cali-
bration-in-the-large 5 0.52 with P ! 0.0001) but re-
mained proportionally accurate (calibration slope 5
0.90). For validation studies 2 and 3, we found an
increased discriminative ability in the validation sample.This increase was expected from step 1 because of an
increased spread of the LP. Although the achieved
calibration-in-the-large and calibration slope were reason-
able for validation study 2, predicted risks were systemat-
ically too low and did not vary enough in validation study 3
(calibration slope: 1.12 with P ! 0.0001).
3.3. Step 3: Interpretation of model validation results
In this final step, we describe how the model’s predictive
accuracy in the validation sample in step 2 can be inter-
preted by combining the results from step 1. We also indi-
cate what may be done to further improve the model’s
performance in the overarching target population of the
validation sample in case of poor performance.
In step 1, we identified whether the reproducibility
(similar case mix) or transportability (different case mix)
of the prediction model is assessed when evaluated in the
validation sample. Step 2 directly indicates whether differ-
ences in case mix between the development and validation
sample actually affect model performance in the latter. Step
2 also indicates whether the discriminative ability of the
prediction model differs because of differences in case
mix heterogeneity (reflected by a different variability of
the LP in step 1) and whether the calibration-in-the-large
deteriorates because of differences in overall (predicted)
outcome frequency (reflected by a different mean of the
LP in step 1).
In case of poor predictive performance in the validation
set, several methods may improve the model’s accuracy in
the validation sample at hand. These updating methods may
range from an intercept update to adjustment or even re-
estimation of individual regression coefficients or adding
predictors [3,11,34,36,37]. Specifically, a poor calibration-
in-the-large may be overcome by re-estimating its intercept
or baseline hazard (if applicable) in the validation sample
(intercept update) [3,11,34,36,37]. Similarly, a poor cali-
bration slope (eg, due to overfitting) may be corrected by
applying an overall adjustment of the calibration slope (lo-
gistic calibration). On the other hand, when predictor ef-
fects are heterogeneous between the development and
validation samples and calibration plots show inconsistent
predictions across the whole range of predicted probabili-
ties, updating becomes more difficult and may require the
re-estimation of individual predictors or even inclusion of
additional predictors. In those scenarios, the validation
study indicates that the model’s predictive mechanisms
may no longer be valid in the validation set; the model thus
poorly transports, and a more substantial model revision or
updating is needed.
3.3.1. Empirical example
In validation study 1, we can conclude that rather the
model’s reproducibility than transportability was tested in
the external validation study and that model performance
was concordantly adequate in the validation sample. The
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Derivation Sample
Predicted probability
A
ct
ua
l p
ro
ba
bi
lit
y
a= 0 (0.07)
b= 1 (0.08)
c= 0.79 (0.01)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Validation Study 1
Predicted probability
A
ct
ua
l p
ro
ba
bi
lit
y
a= −0.52 (0.11)
b= 0.9 (0.11)
c= 0.76 (0.02)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Validation Study 2
Predicted probability
A
ct
ua
l p
ro
ba
bi
lit
y
a= −0.05 (0.1)
b= 0.88 (0.08)
c= 0.82 (0.02)
0.0 0.2 0.4 0.6 0.8 1.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Validation Study 3
Predicted probability
A
ct
ua
l p
ro
ba
bi
lit
y
a= 0.64 (0.07)
b= 1.12 (0.06)
c= 0.85 (0.01)
Fig. 3. Results from step 2 in the empirical example. Calibration plots with 95% confidence intervals of the developed multivariable prediction
model when applied in the development and three validation samples. Perfect calibration is represented by the dotted line through the origin with
slope equal to 1. We generated seven quantile groups predicted probabilities and illustrated their corresponding outcome proportion with a triangle.
a, calibration-in-the-large; b, calibration slope; c, concordance statistic.
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predicted risks were systematically too high (Fig. 4).
For validation studies 2 and 3, we found substantial dif-
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Fig. 4. Results from step 3 in the empirical example: calibration plots after r
able prediction model, revised in validation studies 1 (update of intercept)validation samples. Because the model’s discrimination
improved in the validation sample and its calibration re-
mained fairly adequate, its transportability to the target
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ecalibration in the validation sample. Calibration plot of the multivari-
and 3 (update of intercept and common calibration slope).
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occurred such that the prediction model should be revised,
for example, by updating its intercept and common calibra-
tion slope in the validation sample (Fig. 4).4. Discussion
Studies to quantify the performance of developed exist-
ing prediction models in other individuals (external valida-
tion studies) are important to assess the model’s
performance outside the development setting and to eval-
uate the models’ extent of generalizability [3,4,6e12,16].
It is often unclear how such validation results relate to
generalizability of the prediction model and how re-
searchers should interpret good or poor model performance
observed in a validation sample. We presented a framework
to better interpret the results from (external) validation
studies and to infer whether the external validation study
rather assesses a model’s reproducibility or transportability.
This framework uses concepts that were previously pro-
posed [6,7,14,15]. It hereto distinguishes between (statisti-
cal) reproducibility that can be assessed in individuals who
are from an identical source population, and (clinical)
transportability that can be assessed in individuals who
are from a different but related source population.
With our proposed framework, it becomes possible to
compare the results from different validation studies and
to expose boundaries of model transportability or general-
izability. The underlying rationale bears a strong resem-
blance to John Locke’s doctrine of empiricism [38] and
Karl Popper’s theory of refutability [39e41]. Prediction
models that perform well in validation studies with more
pronounced case mix differences as compared with those
in the development sample are likely to generalize better
across different target populations and, ultimately, to be
more valuable in routine care. It is, however, possible that
some well-developed models are not transportable and may
first require model updating before actual implementation
in another source or target population. The validation re-
sults can then guide the update strategy [35]. Our frame-
work may also be used to expose inflated findings and
spin [42,43]. This may, for instance, occur when re-
searchers deduce optimistic model generalizability from
validation studies with similar case mix as compared with
the development sample. Finally, our framework may be
used to verify whether reported model performance is
reproducible in the original source population. By
rendering validation study results more transparent, it fol-
lows recent recommendations by Ioannidis et al. [44].
The relevance of case mix differences between different
source populations has also been highlighted for studies
evaluating the performance of diagnostic tests [45]. In
particular, it is well known that the accuracy of a diagnostic
test may vary across different study populations, such that
reported estimates cannot directly be translated to popula-
tions with a different case mix. This effect is also known asspectrum bias [14,15]. Furthermore, this issue has also
been described for transporting prediction models across
different settings, such as from secondary to primary care
[3,10,46].
To appreciate our framework and recommendations,
some considerations have to be made. First, in our
framework comparing case mix between development and
validation data sets, one needs the availability of the
participant-level data from the development sample. This
may not always be available to researchers (externally) vali-
dating a previously published prediction model. This im-
plies that accurate calculation of differences in case mix
(step 1) may not directly be possible and makes the interpre-
tation of validation study results in step 3 more difficult. For
this reason, researchers should routinely report the mean
and SD of the LP when developing a novel prediction
model, as this enables comparison of case mix differences
when this model is validated by others with no access to
participant-level data of the development set. The described
approaches in this article could be extended to calculate
case mix differences when only aggregate data or summary
results from the development study are at hand, plus of
course the participant data from the validation study. In
particular, information on the means and covariance of the
predictor variables in the development sample is sufficient
to estimate the membership model (approach 1) or to
compare predicted risks between the development and vali-
dation samples (approach 2). When such information is not
fully reported in the model development article or unavai-
lable from the corresponding authors, it can be borrowed
from the validation sample to reconstruct participant-level
data from the development sample (Appendix Table A1 at
www.jclinepi.com). Finally, case mix differences between
subject characteristics of development and validation sam-
ples can also be evaluated on the average level, by relying
on published baseline tables. Unfortunately, aforementioned
approaches will inevitably mask subtle dissimilarities be-
tween the development and validation samples, reducing po-
tential case mix differences between these samples. The
inability to access IPD from the development study thus
not only complicates interpretation of external validation
study results but may also limit the usefulness of future
external validation studies. Further research is needed to
evaluate how much information about the development sam-
ple is actually required to allow proper distinction between
testing of model’s reproducibility and transportability.
Second, the approaches in this study rely on subject-
level characteristics to evaluate differences in case mix be-
tween the development and validation samples. Differences
in study-level characteristics (such as inclusion and exclu-
sion criteria, details on subject recruitment, or study design
choices) may provide additional insights into achieved
model performance and could therefore further improve
the interpretation of prediction model validation results
(step 3) [47]. For this reason, researchers should clearly
report details on the design of the validation study and
287T.P.A. Debray et al. / Journal of Clinical Epidemiology 68 (2015) 279e289describe how subjects were enrolled in the study. The rele-
vance of study-level characteristics has previously been
highlighted for therapeutic studies, as the generalizability
of estimated treatment effects is often unclear because of
strict inclusion and exclusion criteria [48]. This has lead
to the CONsolidated Standards of Reporting Trials (CON-
SORT) statement, enabling readers to understand a trial’s
design, conduct, analysis, and interpretation and to assess
the validity of its results [49]. Similar guidelines on report-
ing are currently being developed for studies developing or
validating risk prediction models [43,50].
Third, we proposed using a membership model approach
(based on a generalization of Hotelling T2) and the distribu-
tion of the LP approach, to evaluate case-mix differences
between the development and validation samples in a single
dimension. The membership model approach explicitly ac-
counts for differences in subject characteristics, outcome
occurrence, and their interrelation, whereas the distribution
of the LP approach merely compares predicted risk distri-
butions. However, both approaches tend to yield similar
conclusions in our clinical examples. The LP may be less
useful for evaluating case mix differences in survival data
as it does not account for baseline survival. Conversely,
the usefulness of the comparative model strongly depends
on its included variables and may be prone to overfitting.
Other metrics for quantifying the relatedness between
samplesdsuch as the overlap coefficient [51,52] or exten-
sions of the Mahalanobis distance metric [53]dhave not
been evaluated here but may lead to similar conclusions.
Fourth, we noted that differences between the develop-
ment and validation samples beyond parameters (predictors
and outcome) of the prediction model, such as missed
important predictors, may substantially influence a model’s
transportability, as we found in validation study 3 [3,4,6].
These missed predictors could for instance explain differ-
ences in baseline risk or interact with included predictors
[3,4,19,25,32]. Consequently, in such situations, the inter-
pretation of differences in case mix is not always straight-
forward, and clinical expertise remains paramount in
interpreting the results of a model validation study.
Fifth, we used the calibration-in-the-large, the calibration
slope, and the c-statistic as summary statistics for assessing
model performance and interpreting generalizability of a
prediction model. Other measures such as the case-mixe
corrected c-statistic may provide additional insights into
model performance [20]. Furthermore, by focusing on sum-
mary statistics of model calibration (such as calibration-in-
the-large or the calibration slope), precipitate conclusions
about external validity may be reached. For instance, it is
possible that the prediction model shows good calibration
as a whole but yields inaccurate predictions in specific risk
categories. This, in turn, may affect the model’s generaliz-
ability toward these risk categories. We therefore emphasize
the graphing of calibration plots of the model in the valida-
tion sample and visual inspection of these plots in addition
to calculation of the calibration slope [27].Finally, it is important to recognize that good perfor-
mance of a prediction model in another validation sample
does not necessarily correlates with its clinical usefulness.
External validity, as we studied here, relates to statistical val-
idity that considers the whole range of predicted values [6].
Clinical usefulness often implies a threshold value for the
predicted risk or probability above and below which patients
are classified and differently managed [3,4,6,10,27,54].5. Conclusion
The proposed methodological framework for prediction
model validation studies enhances the interpretation of re-
sults from (external) validation studies. The most important
issue is judging to what extent the individuals in the valida-
tion sample are different from the development sample,
how the case mix can be placed in view of other validation
studies of the same model, and to what extent the transport-
ability of the model is studied.Acknowledgments
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